MK-1084-004, NCT06345729: A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% |
|
|
| Recruiting | 3 | 600 | Japan, US, RoW | MK-1084, Placebo, Pembrolizumab, MK-3475, KEYTRUDA ® | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer | 02/29 | 02/31 | | |
